Colburn W A, Jack M L
Department of Pharmacokinetics, Hoffmann-La Roche Inc., Nutley.
Clin Pharmacokinet. 1987 Sep;13(3):179-90. doi: 10.2165/00003088-198713030-00003.
Pharmacokinetic profiles of the 1,4-substituted benzodiazepines are defined by their absorption, distribution, metabolism, and excretion characteristics. An ability to cross the blood-brain barrier and the onset of pharmacological activity have been associated with the physiochemical properties of the benzodiazepines. In addition, drug concentrations in the CSF correlate with the unbound drug concentrations in blood or plasma. Duration of pharmacological activity of the benzodiazepines in humans is associated with the affinity of these compounds for the benzodiazepine receptors in human brain. Therefore, benzodiazepines with high affinity for the benzodiazepine receptor sites in human brain tend to exhibit prolonged half-lives of elimination from the CSF which correlate with the prolonged duration of clinical and pharmacological effects and lower therapeutic doses of these drugs in vivo.
1,4-取代苯二氮䓬类药物的药代动力学特征由其吸收、分布、代谢和排泄特性决定。穿过血脑屏障的能力和药理活性的起效与苯二氮䓬类药物的理化性质有关。此外,脑脊液中的药物浓度与血液或血浆中游离药物浓度相关。苯二氮䓬类药物在人体内的药理活性持续时间与这些化合物对人脑苯二氮䓬受体的亲和力有关。因此,对人脑苯二氮䓬受体位点具有高亲和力的苯二氮䓬类药物往往表现出从脑脊液中消除的半衰期延长,这与临床和药理作用的持续时间延长以及这些药物在体内较低的治疗剂量相关。